NCT06974110 - Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

May 31, 2028

Conditions

Advanced Solid TumorMetastatic Solid TumorEndometrial CancerMSI-H CancerColorectal CancerGastric CancerdMMR Cancer

Interventions

DRUG

MOMA-341

MOMA-341 administered orally

DRUG

Irinotecan

Irinotecan administered by IV infusion

DRUG

Immunotherapy

Immunotherapy administered by IV infusion

Trial Locations (9)

RECRUITING

Investigative Site #128, Tampa

RECRUITING

Investigative Site #120, Detroit

RECRUITING

Investigative Site #127, Dallas

RECRUITING

Investigative Site #122, Sydney

RECRUITING

Investigative Site #123, Westmead

RECRUITING

Investigative Site #124, Woolloongabba

RECRUITING

Investigative Site #125, Adelaide

RECRUITING

Investigative Site #126, Clayton

RECRUITING

Investigative Site #119, Perth